Clinical Trial Update: Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of Niraparib and Dostarlimab (TSR-042) in BRCA-mutated unresectable or metastatic cancers including breast, ovarian, fa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Peritoneal Cancer

Drugs mentioned

• Dostarlimab (dostarlimab)
• Niraparib (Niraparib)

Snippet

Sponsor: University of Washington | Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Status: ACTIVE_NOT_RECRUITING